DPP4 and Hypoglycemia: The subgroup analyses showed that the sequential addition of an SGLT2 inhibitor to a DPP4 inhibitor increased the risk of hypoglycemia compared with the PCB/DPP4i group (RR 2.2, 95% CI 1.3–3.7), whereas the simultaneous combination of the SGLT2i/DPP4i group did not increase the risk of hypoglycemia (RR 1.0, 95% CI 0.4–2.8).